Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT ID: NCT06074588
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
556 participants
INTERVENTIONAL
2023-11-12
2030-03-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sacituzumab tirumotecan
Participants will receive 4 mg/kg of sacituzumab tirumotecan via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle. Additionally, participants receive diphenhydramine (or equivalent), an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of sacituzumab tirumotecan. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.
Sacituzumab tirumotecan
4 mg/kg of MK-sacituzumab tirumotecan by IV infusion
Chemotherapy
Participants will receive 75 mg/m\^2 of docetaxel or 500 mg/m\^2 of pemetrexed by IV infusion on Days 1 and 22 of every 6-week cycle.
Docetaxel
75 mg/m\^2 of docetaxel by IV Infusion
Pemetrexed
500 mg/m\^2 of pemetrexed by IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab tirumotecan
4 mg/kg of MK-sacituzumab tirumotecan by IV infusion
Docetaxel
75 mg/m\^2 of docetaxel by IV Infusion
Pemetrexed
500 mg/m\^2 of pemetrexed by IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documentation of locally assessed radiological disease progression while on or after last treatment based on Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1.
* Participants with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), including a third generation TKI for participants with a T790M mutation; and 1 platinum-based therapy after progression on or after EGFR TKI.
* Measurable disease per RECIST 1.1 as assessed by the local site investigator.
* Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided
* Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization.
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
* Have an ECOG performance status of 0 or 1 within 3 days before randomization.
Exclusion Criteria
* Has mixed tumor(s) with small cell elements.
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
* Has Grade ≥2 peripheral neuropathy.
* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.
* Has an EGFR T790M mutation and has not received a third generation EGFR TKI (eg, osimertinib).
* Received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before randomization.
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
* Completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.
* Received radiation therapy to the lung that is \>30 Gy within 6 months of the first dose of study intervention.
* Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC).
* Received prior treatment with a topoisomerase I-containing ADC.
* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
* Known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Active infection requiring systemic therapy.
* History of noninfectious pneumonitis/ILD that required steroids or has current pneumonitis/ILD.
* Has known active central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable, radiologically stable for at least 4 weeks and do not require glucocorticoids for at least 14 days prior to randomization.
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
* Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Hematology/Oncology - Santa Monica ( Site 0023)
Los Angeles, California, United States
Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0001)
Jacksonville, Florida, United States
Mid Florida Hematology and Oncology Center ( Site 0005)
Orange City, Florida, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003)
Marietta, Georgia, United States
Karmanos Cancer Institute ( Site 0018)
Detroit, Michigan, United States
Mayo Clinic in Rochester, Minnesota-Mayo Clinic Comprehensive Cancer Center ( Site 0027)
Rochester, Minnesota, United States
Hattiesburg Clinic Hematology/Oncology ( Site 0010)
Hattiesburg, Mississippi, United States
University Of Nebraska Medical Center ( Site 0011)
Omaha, Nebraska, United States
Englewood Hospital and Medical Center ( Site 0033)
Englewood, New Jersey, United States
Atlantic Health System Morristown Medical Center ( Site 0031)
Morristown, New Jersey, United States
Capital Health Medical Center - Hopewell ( Site 0006)
Pennington, New Jersey, United States
University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0015)
Cincinnati, Ohio, United States
Tennessee Oncology (0036)
Nashville, Tennessee, United States
University of Texas MD Anderson (0037)
Houston, Texas, United States
VCU Health Adult Outpatient Pavillion ( Site 0026)
Richmond, Virginia, United States
St. George Private Hospital ( Site 3004)
Kogarah, New South Wales, Australia
Westmead Hospital ( Site 3000)
Westmead, New South Wales, Australia
Monash Health-Oncology Research ( Site 3001)
Clayton, Victoria, Australia
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 3003)
Melbourne, Victoria, Australia
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0447)
Natal, Rio Grande do Norte, Brazil
Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0440)
Porto Alegre, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0444)
Barretos, São Paulo, Brazil
Hospital Paulistano-Americas Oncologia ( Site 0441)
São Paulo, , Brazil
A. C. Camargo Cancer Center-CAPEC ( Site 0442)
São Paulo, , Brazil
Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0446)
São Paulo, , Brazil
William Osler Health System ( Site 0205)
Brampton, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0204)
Toronto, Ontario, Canada
Clinica Universidad Catolica del Maule-Oncology ( Site 0501)
Talca, Maule Region, Chile
Centro de Estudios Clínicos SAGA ( Site 0517)
Santiago, Region M. de Santiago, Chile
Orlandi Oncologia-Oncology ( Site 0504)
Santiago, Region M. de Santiago, Chile
FALP-UIDO ( Site 0509)
Santiago, Region M. de Santiago, Chile
K2 Oncology ( Site 0514)
Santiago, Region M. de Santiago, Chile
Clínica RedSalud Vitacura ( Site 0511)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 0502)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 0507)
Santiago, Region M. de Santiago, Chile
Centro Investigacion Cancer James Lind ( Site 0513)
Temuco, Región de la Araucanía, Chile
ONCOCENTRO APYS-ACEREY ( Site 0500)
Viña del Mar, Región de Valparaíso, Chile
Anhui Provincial Cancer Hospital ( Site 2830)
Hefei, Anhui, China
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2810)
Beijing, Beijing Municipality, China
Beijing Peking Union Medical College Hospital-pneumology department ( Site 2815)
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital-Medical Oncology ( Site 2814)
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital ( Site 2819)
Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University ( Site 2820)
Xiamen, Fujian, China
Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 2818)
Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital-Respiratory Oncology ( Site 2816)
Nanning, Guangxi, China
Harbin Medical University Cancer Hospital-oncology of department ( Site 2807)
Harbin, Heilongjiang, China
Henan Cancer Hospital-henan cancer hospital ( Site 2813)
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 2805)
Wuhan, Hubei, China
Wuhan Union Hospital Cancer Center-Cancer Center ( Site 2806)
Wuhan, Hubei, China
Hubei Cancer Hospital ( Site 2809)
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University ( Site 2827)
Changsha, Hunan, China
Hunan Cancer Hospital-thoracic oncology II ( Site 2808)
Changsha, Hunan, China
Nanjing Drum Tower Hospital ( Site 2812)
Nangjing, Jiangsu, China
The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 2821)
Nanchang, Jiangxi, China
Jilin Province Tumor Hospital-clinical research ( Site 2803)
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 2817)
Xi'an, Shaanxi, China
Jinan Central Hospital-oncology department ( Site 2802)
Jinan, Shandong, China
LinYi Cancer Hospital ( Site 2804)
Linyi, Shandong, China
Shanghai Chest Hospital-Oncology department ( Site 2800)
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center-Oncology ( Site 2811)
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University-Lung cancer center ( Site 2826)
Chengdu, Sichuan, China
Sichuan Cancer hospital. ( Site 2822)
Chengdu, Sichuan, China
Yunnan Province Cancer Hospital ( Site 2824)
Kunming, Yunnan, China
Sir Run Run Shaw Hospital School of Medicine Zhejiang University ( Site 2828)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 2829)
Hangzhou, Zhejiang, China
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 1100)
Brno, Brno-mesto, Czechia
Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni odd ( Site 1103)
Ostrava, Ostrava Mesto, Czechia
Fakultni nemocnice Plzen ( Site 1104)
Pilsen, Plzeň Region, Czechia
Fakultni nemocnice Olomouc-Klinika plicnich nemoci a tuberkulozy ( Site 1102)
Olomouc, , Czechia
Vseobecna fakultni nemocnice v Praze-Onkologicka klinika ( Site 1105)
Prague, , Czechia
Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1303)
Bordeaux, Aquitaine, France
CENTRE LEON BERARD ( Site 1305)
Lyon Cedex08, Auvergne-Rhône-Alpes, France
CHU Charles Nicolle-pneumology, intensive care and thoracic oncology ( Site 1300)
Rouen, Haute-Normandie, France
Groupe hospitalier Paris saint Joseph. ( Site 1307)
Paris, , France
Institut Curie-Thorax Institute ( Site 1304)
Paris, , France
Universitaetsklinikum Freiburg ( Site 1405)
Freiburg, Brandenburg, Germany
Universitätsmedizin Göttingen - Georg-August-Universität-Klinik für Hämatologie und Medizinische On ( Site 1407)
Göttingen, Lower Saxony, Germany
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 1400)
Essen, North Rhine-Westphalia, Germany
Klinikum Chemnitz - Flemmingstraße ( Site 1401)
Chemnitz, Saxony, Germany
Universitaetsklinikum Carl Gustav Carus Dresden ( Site 1402)
Dresden, Saxony, Germany
Asklepios Klinik Harburg ( Site 1403)
Hamburg, , Germany
Errikos Dunant Hospital Center-Fourth Department of Oncology and Clinical Trials Unit ( Site 2705)
Athens, Attica, Greece
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 2700)
Athens, Attica, Greece
Aretaieio Hospital ( Site 2702)
Athens, Attica, Greece
ATTIKON GENERAL UNIVERSITY HOSPITAL-Oncology ( Site 2704)
Chaidari, Athens, Attica, Greece
"Theagenio" Cancer Hospital of Thessaloniki ( Site 2703)
Thessaloniki, Central Macedonia, Greece
Papageorgiou General Hospital of Thessaloniki ( Site 2701)
Thessaloniki, , Greece
Hong Kong Integrated Oncology Centre ( Site 3200)
Central, , Hong Kong
Queen Mary Hospital ( Site 3203)
Hksar, , Hong Kong
Queen Elizabeth Hospital-Department of Clinical Oncology ( Site 3204)
Kowloon, , Hong Kong
Princess Margaret Hospital-Department of Oncology ( Site 3201)
Lai Chi Kok, , Hong Kong
Rambam Health Care Campus-Oncology Division ( Site 1702)
Haifa, , Israel
Shaare Zedek Medical Center ( Site 1700)
Jerusalem, , Israel
Rabin Medical Center ( Site 1703)
Petah Tikva, , Israel
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 1806)
Meldola, Emilia-Romagna, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1802)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800)
Milan, Lombardy, Italy
Istituto Clinico Humanitas ( Site 1803)
Rozzano, Lombardy, Italy
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1805)
Rome, Roma, Italy
Aichi Cancer Center ( Site 3400)
Nagoya, Aichi-ken, Japan
Fujita Health University Hospital ( Site 3419)
Toyoake, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 3406)
Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center ( Site 3415)
Matsuyama, Ehime, Japan
Gunma Prefectural Cancer Center ( Site 3418)
Otashi, Gunma, Japan
Takarazuka City Hospital ( Site 3409)
Takarazuka, Hyōgo, Japan
Kanazawa University Hospital ( Site 3414)
Kanazawa, Ishikawa-ken, Japan
Kanagawa Cancer Center ( Site 3404)
Yokohama, Kanagawa, Japan
Miyagi Cancer Center ( Site 3416)
Natori-shi, Miyagi, Japan
Sendai Kousei Hospital ( Site 3401)
Sendai, Miyagi, Japan
Niigata Cancer Center Hospital ( Site 3405)
Niigata, Niigata, Japan
Kansai Medical University Hospital ( Site 3410)
Hirakata, Osaka, Japan
Shizuoka Cancer Center ( Site 3403)
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
Cancer Institute Hospital of JFCR ( Site 3402)
Koto, Tokyo, Japan
Chiba University Hospital ( Site 3411)
Chiba, , Japan
National Hospital Organization Kyushu Medical Center ( Site 3412)
Fukuoka, , Japan
Kyushu University Hospital ( Site 3407)
Fukuoka, , Japan
Okayama University Hospital ( Site 3417)
Okayama, , Japan
Osaka International Cancer Institute ( Site 3413)
Osaka, , Japan
Nippon Medical School Hospital ( Site 3408)
Tokyo, , Japan
Hospital Raja Perempuan Zainab II-Medical Department ( Site 3502)
Kota Bharu, Kelantan, Malaysia
National Cancer Institute-Radiotherapy and Oncology ( Site 3504)
Putrajaya, Kuala Lumpur, Malaysia
Sarawak General Hospital-Radiotherapy Unit ( Site 3500)
Kuching, Sarawak, Malaysia
CIO - Centro de Inmuno-Oncología de Occidente ( Site 0706)
Guadalajara, Jalisco, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 0704)
Monterrey, Nuevo León, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 0701)
Oaxaca City, Oaxaca, Mexico
Clinica Integral Internacional de Oncología ( Site 0705)
Puebla City, , Mexico
THE MEDICAL CITY ILOILO-The Medical City Iloilo - Clinical and Translational Research Institute-Ilo ( Site 3600)
Iloilo City, Iloilo, Philippines
Manila Doctors Hospital-Clinical Trial Office ( Site 3604)
Manila, National Capital Region, Philippines
Asian Hospital and Medical Center ( Site 3605)
Muntinlupa, National Capital Region, Philippines
THE MEDICAL CITY-Cancer Research Center ( Site 3603)
Pasig, National Capital Region, Philippines
ST. LUKE'S MEDICAL CENTER ( Site 3601)
Quezon City, National Capital Region, Philippines
CARDINAL SANTOS MEDICAL CENTER-Research Room ( Site 3602)
San Juan City, Metro Manila, National Capital Region, Philippines
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2003)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 2009)
Torun, Kuyavian-Pomeranian Voivodeship, Poland
Instytut Gruźlicy i Chorób Płuc w Warszawie ( Site 2011)
Warsaw, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 2000)
Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 2001)
Przemyśl, Podkarpackie Voivodeship, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach-II Klinika Radioterapi i Chemioterapii ( Site 2002)
Gliwice, Silesian Voivodeship, Poland
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2005)
Kielce, Świętokrzyskie Voivodeship, Poland
Chonnam National University Hwasun Hospital-Pulmonology ( Site 3807)
Hwasun, Jeonranamdo, South Korea
National Cancer Center-Lung Cancer Center ( Site 3810)
Goyang-si, Kyonggi-do, South Korea
Seoul National University Bundang Hospital ( Site 3806)
Seongnam, Kyonggi-do, South Korea
The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 3803)
Suwon, Kyonggi-do, South Korea
Pusan National University Yangsan Hospital-Lung Cancer Clinic ( Site 3811)
Yangsan, Kyongsangnam-do, South Korea
Chungbuk National University Hospital-Internal medicine ( Site 3809)
Cheongju-si, North Chungcheong, South Korea
Pusan National University Hospital ( Site 3805)
Busan, Pusan-Kwangyokshi, South Korea
Chungnam national university hospital ( Site 3808)
Junggu, Taejon-Kwangyokshi, South Korea
Kangbuk Samsung Hospital ( Site 3813)
Seoul, , South Korea
Severance Hospital, Yonsei University Health System-Lung Cancer Center ( Site 3804)
Seoul, , South Korea
Konkuk University Medical Center ( Site 3812)
Seoul, , South Korea
Asan Medical Center ( Site 3801)
Seoul, , South Korea
Samsung Medical Center-Division of Hematology/Oncology ( Site 3802)
Seoul, , South Korea
Korea University Guro Hospital-Internal Medicine ( Site 3800)
Seoul, , South Korea
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 2304)
Barcelona, Catalonia, Spain
Hospital Insular de Gran Canaria-Oncology ( Site 2305)
Las Palmas de Gran Canaria, Las Palmas, Spain
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2301)
Pozuelo de Alarcón, Madrid, Spain
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2303)
Madrid, Madrid, Comunidad de, Spain
H.R.U Málaga - Hospital General-Oncology ( Site 2302)
Málaga, Malaga, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2300)
Barcelona, , Spain
Clinica Universidad de Navarra-Medical Oncology ( Site 2306)
Madrid, , Spain
Chi Mei Medical Center ( Site 3910)
Tainan, Tainan, Taiwan
National Taiwan University Cancer Center (NTUCC) ( Site 3903)
Taipei City, Taipei, Taiwan
Changhua Christian Hospital ( Site 3908)
Changhua, , Taiwan
National Taiwan University Hospital - Hsinchu branch ( Site 3907)
Hsinchu, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 3912)
Kaohsiung City, , Taiwan
E-Da hospital ( Site 3911)
Kaohsiung City, , Taiwan
Chang Gung Memorial Hospital at Kaohsiung ( Site 3906)
Kaohsiung City, , Taiwan
National Cheng Kung University Hospital ( Site 3909)
Tainan, , Taiwan
National Taiwan University Hospital-Oncology ( Site 3904)
Taipei, , Taiwan
Mackay Memorial Hospital-Chest Medicine ( Site 3902)
Taipei, , Taiwan
Taipei Medical University Hospital ( Site 3900)
Taipei, , Taiwan
Faculty of Medicine Siriraj Hospital ( Site 4000)
Bangkok, Bangkok, Thailand
Lampang Cancer Hospital ( Site 4005)
Muang, Changwat Lampang, Thailand
Songklanagarind hospital ( Site 4001)
Hat Yai, Changwat Songkhla, Thailand
Maharaj Nakorn Chiang Mai Hospital ( Site 4003)
Muang, Chiang Mai, Thailand
Faculty of Medicine - Khon Kaen University ( Site 4004)
Khon Kaen, , Thailand
Sunpasitthiprasong Hospital-Oncology ( Site 4002)
Ubon Ratchathani, , Thailand
Medipol Mega Universite Hastanesi-oncology ( Site 2505)
Stanbul, Istanbul, Turkey (Türkiye)
Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2504)
Bornova, İzmir, Turkey (Türkiye)
Adana Medical Park Seyhan Hastanesi ( Site 2506)
Adana, , Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 2500)
Ankara, , Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 2501)
Ankara, , Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2502)
Istanbul, , Turkey (Türkiye)
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2606)
London, Kensington and Chelsea, United Kingdom
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 2600)
London, London, City of, United Kingdom
Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 2603)
London, London, City of, United Kingdom
Royal Marsden Hospital (Sutton) ( Site 2605)
Sutton, Surrey, United Kingdom
The Christie NHS Foundation Trust ( Site 2604)
Manchester, , United Kingdom
The Clatterbridge Cancer Centre ( Site 2602)
Metropolitan Borough of Wirral, , United Kingdom
Hanoi Oncology Hospital ( Site 4102)
Hanoi, Hanoi, Vietnam
K Hospital - National Cancer Hospital ( Site 4105)
Hanoi, Hanoi, Vietnam
National Lung Hospital-Oncology Department ( Site 4104)
Hanoi, Hanoi, Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Tamjeed Ahmed
Role: primary
Yasir Elamin
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-503539-16-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
jRCT2031240108
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1287-4913
Identifier Type: REGISTRY
Identifier Source: secondary_id
2870-004
Identifier Type: -
Identifier Source: org_study_id